nafamostat has been researched along with Breast Cancer in 1 studies
nafamostat: inhibitor of trypsin, plasmin, pancreatic kallikrein, plasma kallikrein & thrombin; strongly inhibits esterolytic activities of C1r & C1 esterase complement-mediated hemolysis; antineoplastic
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Pant, SM | 1 |
| Mukonoweshuro, A | 1 |
| Desai, B | 1 |
| Ramjee, MK | 1 |
| Selway, CN | 1 |
| Tarver, GJ | 1 |
| Wright, AG | 1 |
| Birchall, K | 1 |
| Chapman, TM | 1 |
| Tervonen, TA | 1 |
| Klefström, J | 1 |
1 other study available for nafamostat and Breast Cancer
| Article | Year |
|---|---|
Design, Synthesis, and Testing of Potent, Selective Hepsin Inhibitors via Application of an Automated Closed-Loop Optimization Platform.
Topics: Breast Neoplasms; Cell Proliferation; Drug Design; Enzyme Inhibitors; Female; High-Throughput Screen | 2018 |